申请人:TAISHO PHARMACEUTICAL CO., LTD
公开号:EP2077271A1
公开(公告)日:2009-07-08
Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).
式(I)和式(IV)所代表的化合物具有抑制MMP-9生成的活性,因此,与传统的MMP酶活性抑制剂相比,该化合物是一种副作用较小的药物,可作为肿瘤性血管生成、慢性类风湿性关节炎的预防和治疗药物、经皮冠状动脉腔内血管成形术后血管内膜增厚、血管粥样硬化、出血性心肌梗塞、急性心肌梗塞、慢性心力衰竭、动脉瘤、肺癌转移、成人呼吸窘迫综合征、哮喘、间质性肺纤维化、慢性鼻炎、支气管炎或慢性阻塞性肺病(COPD)。